Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session of pioneering JAK science. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.
Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatic diseases often becomes difficult and needs specialized attention which can be gained from this webinar.
The webinar will help in gaining important insights on JAK or Janus Kinase's family. The family includes Jak1, Jak2, Jak3, and Tyk2 which are involved in cell growth, development, and differentiation of the cells.
Get detailed information on the pathways involving JAK and how the JAK inhibiting drugs (tofacitinib) acts in controlling the progression of rheumatic diseases from this session.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
See More Webinars @ Hidoc Webinars
1.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
2.
Research uncovers hidden Australian skin cancer epidemic
3.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
4.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
5.
The American College of Physicians updated its recommendations for colorectal cancer screening.
1.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation